Development of innovative immunotherapeutic drugs, exploration of specialized knowledge aimed at research results of next-generation antibody fusion proteins
Innovative technological capabilities are being studied and developed by a group of accomplished immunologists with world-class expertise and extensive experience in academic research and drug research and development.
Currently approved drugs for autoimmune diseases mainly target inflammatory cytokines such as TNF?. Since these drugs usually focus on the alleviation of the symptoms not on the immune cells causing the disease, there are critical unmet needs in improving clinical benefits in non-responders and patients relapsed. With GX-P1 and GX-P10, Genexine is pursuing fundamental approach to the disease-causing immune cells in which the auto-reactive immune cells are controlled by suppressive PD-1/PD-L1 signaling and also by additional combination twith immunosuppressive cytokine.